Sanofi, DNDi seek EMA review for sleeping sickness treatment

1 Feb 2018

Fexinidazole would be first all-oral treatment under investigation for both first and second stages of sleeping sickness, a fatal disease, endemic in Africa.

Sanofi has asked the EMA to review fexinidazole for the treatment of sleeping sickness. Fexinidazole is being developed in collaboration with the Drugs for Neglected Disease initiative (DNDi). It would be the first all-oral treatment under investigation for Trypanosoma brucei gambiense human African trypanosomiasis (g-HAT), commonly known as sleeping sickness. It is hoped that this treatment will contribute to the elimination of the disease.

Sanofi, DNDi seek EMA review for sleeping sickness treatment
The tsetse fly - the main vector for sleeping sickness.

EMA has accepted the application under a special procedure called "Article 58" which allows the EMA to give a scientific opinion, in co-operation with the World Health Organization (WHO), for the evaluation of medicinal products that are intended exclusively for markets outside of the European Union. Fexinidazole was previously granted accelerated assessment by the EMA.

"The acceptance by the EMA of the fexinidazole regulatory dossier is a critical step in the registration process," said Dr Nathalie Strub-Wourgaft, DNDi Medical Director. "Results of the Phase II/III clinical trials conducted with our partners in Democratic Republic of Congo and the Central African Republic showed the product to be effective and well tolerated."

Following the evaluation of the dossier, the EMA will publish its scientific opinion of the benefit risk of the treatment, which will facilitate the registration of fexinidazole in HAT-endemic countries.

"This milestone is the result of an innovative collaboration between Sanofi and DNDi to address the burden of sleeping sickness," said Dr Ameet Nathwani, Chief Medical Officer, Sanofi. "Fexinidazole is being developed with the goal of addressing all stages of sleeping sickness and simplifying treatment by avoiding systematic hospitalization. It could represent a therapeutic breakthrough foremost for the patients and potentially support elimination efforts as per the WHO 2020 Roadmap."

Read More

Related news

Allergan to establish R&D presence in Cambridge, Massachusetts

Allergan to establish R&D presence in Cambridge, Massachusetts

10 Jan 2019

The new, strategic presence will allow the company to more easily interact and engage with venture firms and start ups in the area.

Read more 
Expedeon signs supply and license agreement for is Lightning-Link technology

Expedeon signs supply and license agreement for is Lightning-Link technology

9 Jan 2019

The technology will enable Cell Guidance Systems to manufacture TRIFic detection assays on-demand with highly reproducible and scalable results.

Read more 
WuXi AppTec expands site in California for pharmaceutical R&D services

WuXi AppTec expands site in California for pharmaceutical R&D services

13 Dec 2018

Expanded facility will establish a center of excellence in screening, discovery biology, pharmacology, and small molecule process R&D including Phase I GMP manufacturing.

Read more 
Cambrex expands analytical capabilities

Cambrex expands analytical capabilities

12 Dec 2018

The $1 million investment will assist in getting new products to commercial launch faster.

Read more 
MIT engineers repurpose wasp venom as an antibiotic drug

MIT engineers repurpose wasp venom as an antibiotic drug

9 Dec 2018

Altered peptides from a South American wasp’s venom can kill bacteria but are nontoxic to human cells.

Read more 
Spanish CDMO working ahead of EU serialisation deadline

Spanish CDMO working ahead of EU serialisation deadline

6 Dec 2018

Company now able to serialise commercial batches manufactured by them for clients; it can also offer standalone serialisation services as an outsourcing partner.

Read more 
Fluidic Analytics raises $31m to launch new lab tools and unlock biology behind major diseases

Fluidic Analytics raises $31m to launch new lab tools and unlock biology behind major diseases

5 Dec 2018

The financing will power the global commercial launch of the company's Fluidity One system.

Read more 
OnDosis and Recipharm partner to advance a novel treatment regimen for ADHD

OnDosis and Recipharm partner to advance a novel treatment regimen for ADHD

4 Dec 2018

The new treatment will leverage OnDosis’ proprietary technology, which integrates oral drugs in form of micro units and individualised dosing, in a handheld device.

Read more 
NIH to evaluate effectiveness of male contraceptive skin gel

NIH to evaluate effectiveness of male contraceptive skin gel

28 Nov 2018

The gel formulation includes the progestin compound segesterone acetate, in combination with testosterone, and is applied to the back and shoulders and absorbed through the skin.

Read more 
QPS expands US-based Phase I clinical trial capabilities

QPS expands US-based Phase I clinical trial capabilities

27 Nov 2018

Expansion supports the growing needs of the company's pharmaceutical, biotechnology and CRO partners.

Read more